Enanta Pharmaceuticals, Inc. (ENTA)

Market Cap	334.07M +42.6%
Revenue (ttm)	65.26M +0.7%
Net Income	-63.23M
EPS	-2.34
Shares Out	29.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,425
Open	11.34
Previous Close	11.18
Day's Range	11.22 - 11.75
52-Week Range	10.20 - 17.15
Beta	0.96
Analysts	Strong Buy
Price Target	21.83 (+90.32%)
Est. Earnings	Nov 16, 2026

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 21, 2013
• Employees: 120
• Stock Exchange: Nasdaq
• Ticker Symbol: ENTA
• Website: https://www.enanta.com

Financial Performance

In fiscal year 2025, Enanta Pharmaceuticals's revenue was $65.32 million, a decrease of -3.42% compared to the previous year's $67.64 million. Losses were -$81.89 million, -29.43% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for ENTA stock is "Strong Buy." The 12-month stock price target is $21.83, which is an increase of 90.32% from the latest price.

Price Target

$21.83

(90.32% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error